IGI'S PTH 1-34 SLATED FOR PHASE II TRIAL BY MANHATTAN FOR THE TREATMENT OF PSORIASIS

IGI has announced that, assuming successful completion of the proposed merger between Manhattan Pharmaceuticals and Tarpan Therapeutics, Manhattan Pharmaceuticals intends to pursue a Phase II clinical trial for PTH (1-34) using IGI's Novasome nanovesicular topical delivery technology.

As previously announced, IGI signed a sublicense agreement with Tarpan for the clinical uses of PTH (1-34) relating to the regulation of cell differentiation and proliferation for treatment of skin disorders using IGI's Novasome nanovesicular topical delivery technology.

PTH (1-34), a peptide believed to be a regulator of epidermal cell growth and differentiation, is currently under development as a topical treatment for psoriasis and additional dermatological indications.